-
How are African countries advancing vaccine production?
African countries are making strides by conducting clinical trials and developing vaccines locally. South Africa is testing a fully manufactured cholera vaccine, aiming for approval by 2028, while Nigeria is progressing with a Lassa fever vaccine supported by international partners like CEPI. These efforts are part of a broader push to build vaccine manufacturing capacity across the continent.
-
What vaccines are being developed locally in Africa?
Currently, South Africa is working on a cholera vaccine through clinical trials, with plans for local production. Nigeria is developing a Lassa fever vaccine, which is a major regional health concern. Both projects aim to produce vaccines domestically, reducing reliance on imports and improving access during outbreaks.
-
When will Nigeria and South Africa's vaccines be available?
South Africa's cholera vaccine is expected to be approved and available by 2028, following successful clinical trials. Nigeria's Lassa fever vaccine is also targeting a similar timeline, with ongoing development and regulatory processes. These timelines reflect the progress made but depend on successful trials and approvals.
-
How does vaccine self-reliance impact regional health security?
Building vaccine self-reliance helps African countries respond more quickly to outbreaks, reduces dependency on global supply chains, and enhances overall health security. It also allows for vaccines tailored to regional health needs, which can improve effectiveness and coverage during health crises.
-
What challenges do African countries face in vaccine development?
Africa faces challenges like limited clinical trial capacity, funding constraints, and infrastructure gaps. Only about 1.1% of global trials are conducted on the continent, which hampers vaccine development. Initiatives like CEPI aim to address these issues by strengthening research, regulation, and manufacturing capabilities.
-
Why is local vaccine production important for Africa?
Local vaccine production reduces dependence on imports, shortens supply chains, and ensures quicker access during outbreaks. It also supports regional health sovereignty and can lead to more affordable vaccines tailored to local needs, ultimately saving lives and strengthening health systems.